Key terms
About PLRX
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PLRX news
Mar 13
7:11am ET
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)
Mar 12
12:50pm ET
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX)
Mar 12
7:48am ET
Pliant Therapeutics announces accelerated bexotegrast development plan
Mar 08
7:56am ET
Pliant Therapeutics: Strong Buy Rating on Promising Pipeline and Solid Financials
Mar 01
1:00am ET
Maintaining Buy Rating on Pliant Therapeutics: Promising Clinical Advances and Solid Financial Footing
Feb 29
6:40am ET
Buy Rating Affirmed for Pliant Therapeutics Amid Promising Drug Pipeline and Financial Stability
Feb 28
7:47am ET
Oppenheimer Keeps Their Buy Rating on Pliant Therapeutics (PLRX)
Feb 28
7:40am ET
Pliant Therapeutics price target lowered to $50 from $53 at RBC Capital
Feb 28
7:31am ET
Piper Sandler Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)
Feb 28
7:16am ET
Pliant Therapeutics (PLRX) Gets a Buy from RBC Capital
Feb 28
6:50am ET
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX) and Viridian Therapeutics (VRDN)
Feb 28
6:38am ET
Buy Rating Affirmed for Pliant Therapeutics Amidst Promising Clinical Trial Progress
Feb 28
6:26am ET
Buy Rating Affirmed for Pliant Therapeutics on Promising Pipeline and Strong Financials
Feb 28
2:09am ET
3 Best Stocks to Buy Now, 2/28/2024, According to Top Analysts
Feb 27
10:20pm ET
Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX)
Feb 27
9:27pm ET
Pliant Therapeutics (PLRX) Receives a Buy from TD Cowen
Feb 27
4:24pm ET
Pliant Therapeutics reports Q4 EPS (69c), consensus (81c)
Feb 08
7:19am ET
Pliant Therapeutics price target lowered to $43 from $48 at Canaccord
Feb 07
8:31am ET
Buy Rating on Pliant Therapeutics: Positive Outlook on Bexotegrast Despite Investor Concerns
Feb 06
7:29am ET
Pliant Therapeutics price target lowered to $47 from $49 at Oppenheimer
Feb 06
5:39am ET
Buy Rating on Pliant Therapeutics: Promising IPF Drug Outlook Overcomes PSC Concerns
Feb 06
4:16am ET
Pliant Therapeutics Achieves Success in Liver Disease Trial
Feb 06
4:08am ET
3 Best Stocks to Buy Now, 2/6/2024, According to Top Analysts
Feb 05
1:45pm ET
Pliant Therapeutics: Overcoming PSC Trial Hurdles with Promising IPF Prospects
Feb 05
8:35am ET
Piper Sandler Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
Feb 05
8:15am ET
Pliant Therapeutics (PLRX) Receives a Buy from Stifel Nicolaus
Feb 05
6:20am ET
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Siemens Healthineers AG (OtherSEMHF) and 4D Molecular Therapeutics (FDMT)
Feb 05
6:14am ET
Pliant Therapeutics price target lowered to $48 from $52 at H.C. Wainwright
Feb 04
4:42pm ET
Pliant Therapeutics announces data from INTEGRIS-PSC Phase 2a trial
Jan 07
5:39am ET
BTIG Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
Jan 02
12:13pm ET
The biotech stocks to own in 2024, according to Piper Sandler
No recent press releases are available for PLRX
PLRX Financials
Key terms
Ad Feedback
PLRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PLRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
